GSK3 (Glycogen Synthase Kinase-3) is a ubiquitously expressed, highly conserved serine/threonine protein kinase found in all eukaryotes. Originally identified as a regulator of glycogen metabolism, GSK3 acts as a downstream regulatory switch for numerous signaling pathways, including cellular responses to WNT, growth factors, insulin, receptor tyrosine kinases (RTK), Hedgehog pathways, and G-protein-coupled receptors (GPCR). It is involved in a wide range of signal transduction cascades involving cellular processes, ranging from glycogen metabolism, cell development, gene transcription, and protein translation to cytoskeletal organization, cell cycle regulation, proliferation, and apoptosis. Unlike most protein kinases involved in signaling, GSK3 is active in unstimulated, resting cells and its activity is diminished during cellular responses. Another peculiarity is its preference for primed substrates; that is, substrates previously phosphorylated by another kinase . Growth factors and insulin signaling inhibit the ability of GSK3 to act on pre-phosphorylated (primed) substrates by phosphorylating Ser9 of GSK3, which then blocks the interaction of GSK3 with the phosphate group on primed substrates. GSK3 is localized predominantly in the cytoplasm but is also found in the nucleus. Its subcellular localization is changed in response to stimuli .
There are two mammalian GSK3 isoforms encoded by distinct genes: GSK3-Alpha and GSK3-Beta. GSK3-Beta is particularly abundant in the central nervous system (CNS) and directly phosphorylates several neuronal microtubule-associated proteins (MAPs) involved in microtubule stabilization . GSK3 is negatively regulated by of Phosphatidylinositol 3-Kinase (PI3K)-mediated activation of Akt/Protein kinase B (PKB) and by the WNT signaling pathway  . In the absence of a WNT signal, GSK3 is a part of the multiprotein complex that includes the proteins axis inhibitor (AXIN), adenomatous polyposis coli (APC), casein kinase 1 (CSNK1), and beta-catenin (Beta-Ctnn), which is localized at the membrane along with the cadherins. These proteins help GSK3 to efficiently phosphorylate the signaling molecule Beta-Ctnn, thus targeting it for ubiquitination and subsequent proteasomal degradation. AXIN acts as a scaffolding protein in this complex, binding both GSK3 and Beta-Ctnn in a manner that brings them into close proximity, thus allowing GSK3 to phosphorylate Beta-Ctnn. AXIN therefore acts as a GSK3-activating protein. When GSK3 is active, it phosphorylates APC and Beta-Ctnn and stimulates interaction between Beta-Ctnn and beta-transducin repeat-containing protein (Beta-TRCP), a regulator of E3 ubiquitin ligase, which degrades Beta-Ctnn in proteasomes [4,10]. GSK3 phosphorylates a variety of substrates other than Beta-Ctnn, such as glycogen synthase and other metabolic enzymes, transcription factors CREB binding protein (CBP), c-Myc and c-Jun, and the translation initiation factors eIF2 and eIF2B . Phosphorylation of transcription factors by GSK3-Beta causes ubiquitination or nuclear exit or decreases in the DNA binding, leading to a decrease in nuclear transcription . In neuronal cells, GSK3 phosphorylates a number of MAPs, such as MAP2C, MAP1B, and Tau. Phosphorylation of these proteins by GSK3 decreases their ability to stabilize microtubules .
Binding of the WNT molecules to Frizzled (Fz) receptors activates Dishevelled (Dsh) through G-proteins G-AlphaQ and G-AlphaO, which inhibits the activity of GSK3, thereby stabilizing Beta-Ctnn. CSNKI also makes a complex with AXIN, GSK3, and Dsh and works as a positive regulator of WNT signaling. Stabilization of Beta-Ctnn is associated with its translocation to the nucleus in presence of Protein Phosphatase-2A (PP2A) where it interacts with members of the (Lymphoid Enhancer Factor (LEF)/T-Cell Factor (TCF) and activates specific target genes . When Beta-Ctnn is absent, certain TCFs repress transcription by interacting with the corepressors TLE Transducin-Like Enhancer (TLE) and C-Terminal Binding Protein (CTBP). Another GSK3-interacting molecule, GSK3 Binding Protein (GBP), and its mammalian homologue Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT), binds to GSK3 and inhibits its phosphorylation of non-primed GSK3 substrates, including Beta-Ctnn. GBP/FRAT compete with AXIN for binding to GSK3, resulting in GSK3 inhibition . Numerous other stimuli also lead to inactivation of GSK3, including growth factors such as EGF epidermal growth factor (EGF) and PDGF platelet-derived growth factor (PDGF) that stimulate the GSK3-inactivating kinase p90RSK (also known as MAPKAPK1) through RasGTP-MAPK (mitogen-activated protein kinase), activators of p70 ribosomal S6 kinase (p70S6K) such as amino acids, activators of cAMP-activated PKA (protein kinase A) . GSK3 induces Caspase3 activation and activates the proapoptotic tumor suppressor gene, p53. It also promotes activation and translocation of the proapoptotic B-cell Lymphomal Leukaemia (BCL2) family member, BAX (BCL2 Associated X-protein), which, upon aggregation and mitochondrial localization, induces cytochrome c (CytoC) release. Akt is one of the critical regulators of GSK3, and phosphorylation and inactivation of GSK3 may mediate some of the antiapoptotic effects of Akt .
GSK3 is a key regulator in several physiological processes, such as cell cycle, oncogenesis, and apoptosis in neuronal cells and vascular smooth muscle cells (VSMC) during hypoxia . Increased cAMP levels promote survival of neuronal cells by inactivating GSK3 via a PKA–dependent mechanism . Many of the pathways that use GSK3 as a regulator have links to human diseases. GSK3 has been implicated in non-insulin-dependent Diabetes Mellitus and generation of neurofibrillary tangles (NFT) associated with Alzheimer’s disease  as well as several hallmarks of Alzheimer's disease, including neurodegeneration, reactive astrocytosis, microgliosis, and the formation of apoptotic bodies . The tangles are formed from hyperphosphorylated Tau. GSK3-Beta negatively regulates cardiac hypertrophy and cardiac development through its effect on WNT signaling . Recently, a number of potent and selective GSK3 inhibitors have been developed having several therapeutic uses, including the treatment of neurodegenerative disease, bipolar disorder, and inflammatory disease . However, the best-characterized inhibitor of GSK3 is lithium. Although inhibition of GSK3 may be desirable in one context (e.g., preventing neuronal apoptosis), it could have serious implications for another—for example, it might accelerate hyperplasia by deregulating Beta-Ctnn. Given the involvement of GSK3 in many pathophysiological processes and diseases, GSK3 is a tempting therapeutic target .
- Smillie KJ, Cousin MA (2011) The Role of GSK3 in Presynaptic Function. Int J Alzheimers Dis 2011:263673.
- Medina M, Wandosell F (2011) Deconstructing GSK-3: The Fine Regulation of Its Activity. Int J Alzheimers Dis 2011:479249. Epub 2011 Apr 28.
- Sutherland C (2011) What Are the bona fide GSK3 Substrates? Int J Alzheimers Dis 2011:505607. Epub 2011 May 18.
- Luo J (2009) Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 273(2):194-200. Epub 2008 Jul 7.
- Voskas D, Ling LS, Woodgett JR (2010) Does GSK-3 provide a shortcut for PI3K activation of Wnt signalling? F1000 Biol Rep 2:82.
- Hur EM, Zhou FQ (2010) GSK3 signalling in neural development. Nat Rev Neurosci 11(8):539-51.
- Ong Tone S, Dayanandan B, Fournier AE, et al. (2010) GSK3 regulates mitotic chromosomal alignment through CRMP4. PLoS One 5(12):e14345.
- Deng H, Hershenson MB, Lei J, et al. (2010) Pulmonary artery smooth muscle hypertrophy: roles of glycogen synthase kinase-3beta and p70 ribosomal S6 kinase. Am J Physiol Lung Cell Mol Physiol 298(6):L793-803. Epub 2010 Feb 26.
- Kaufmann L, Marinescu G, Nazarenko I, et al. (2011) LiCl induces TNF-a and FasL production, thereby stimulating apoptosis in cancer cells. Cell Commun Signal 9:15.
- Jiang H, Lu Y, Yuan L, et al. (2011) Regulation of interleukin-10 receptor ubiquitination and stability by beta-TrCP-containing ubiquitin E3 ligase. PLoS One 6(11):e27464. Epub 2011 Nov 8.